3918-84-1 Usage
Description
H-GLU-ASP-OH, also known as L-glutamyl-L-aspartic acid, is a dipeptide composed of L-glutamic acid and L-aspartic acid joined by a peptide linkage. It is a white powder and is known for its potential applications in various industries due to its unique properties.
Uses
Used in Pharmaceutical Industry:
H-GLU-ASP-OH is used as a pharmaceutical compound for its potential therapeutic applications. The dipeptide structure allows it to interact with various biological systems, making it a promising candidate for drug development and treatment of certain medical conditions.
Used in Cosmetic Industry:
In the cosmetic industry, H-GLU-ASP-OH is used as an ingredient in skincare products for its moisturizing and skin-protecting properties. The dipeptide can help improve skin hydration and maintain the skin's natural barrier function.
Used in Food Industry:
H-GLU-ASP-OH is used as an additive in the food industry to enhance flavor, texture, and shelf life. The dipeptide can act as a taste enhancer and improve the overall quality of various food products.
Used in Research and Development:
H-GLU-ASP-OH is used as a research tool in the field of biochemistry and molecular biology. The dipeptide can be utilized in the study of peptide synthesis, protein-protein interactions, and other biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 3918-84-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,9,1 and 8 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 3918-84:
(6*3)+(5*9)+(4*1)+(3*8)+(2*8)+(1*4)=111
111 % 10 = 1
So 3918-84-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H14N2O7/c10-4(1-2-6(12)13)8(16)11-5(9(17)18)3-7(14)15/h4-5H,1-3,10H2,(H,11,16)(H,12,13)(H,14,15)(H,17,18)
3918-84-1Relevant articles and documents
Compositions and Methods for Binding Lysophosphatidic Acid
-
, (2009/06/27)
Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.
Green fluorescent protein fusions with random peptides
-
, (2008/06/13)
The invention relates to the use of fluorescent proteins, particularly green fluorescent protein (GFP), in fusion constructs with random and defined peptides and peptide libraries, to increase the cellular expression levels, decrease the cellular catabolism, increase the conformational stability relative to linear peptides, and to increase the steady state concentrations of the random peptides and random peptide library members expressed in cells for the purpose of detecting the presence of the peptides and screening random peptide libraries. N-terminal, C-terminal, dual N- and C-terminal and one or more internal fusions are all contemplated. Novel fusions utilizing self-binding peptides to create a conformationally stabilized fusion domain are also contemplated.
